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We recently observed that dysregulation of the complement system may be involved in the pathogenesis of
hematopoietic stem cell transplantationeassociated thrombotic microangiopathy (HSCT-TMA). These ﬁndings
suggest that the complement inhibitor eculizumab could be a therapeutic option for this severe HSCT
complication with high mortality. However, the efﬁcacy of eculizumab in children with HSCT-TMA and its
dosing requirements are not known. We treated 6 children with severe HSCT-TMA using eculizumab and
adjusted the dose to achieve a therapeutic level >99 mg/mL. HSCT-TMA resolved over time in 4 of 6 children
after achieving therapeutic eculizumab levels and complete complement blockade, as measured by low total
hemolytic complement activity (CH50). To achieve therapeutic drug levels and a clinical response, children
with HSCT-TMA required higher doses or more frequent eculizumab infusions than currently recommended
for children with atypical hemolytic uremic syndrome. Two critically ill patients failed to reach therapeutic
eculizumab levels, even after dose escalation, and subsequently died. Our data indicate that eculizumab may
be a therapeutic option for HSCT-TMA, but HSCT patients appear to require higher medication dosing than
recommended for other conditions. We also observed that a CH50 level  4 complement activity enzyme
units correlated with therapeutic eculizumab levels and clinical response, and therefore CH50 may be useful
to guide eculizumab dosing in HSCT patients as drug level monitoring is not readily available.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION needed for patients with severe HSCT-TMA in whom
Hematopoietic stem cell transplantationeassociated
thrombotic microangiopathy (HSCT-TMA) is a challenging
post-transplant complication associated with long-term
morbidity and high mortality [1-3]. HSCT-TMA shares
features with other TMAs where endothelial injury affects
the kidney and other organs. Mild HSCT-TMA may have a
benign course that requires no therapy or only modiﬁca-
tion of calcineurin inhibitor dosing [4,5]. However, a
proportion of cases develop a systemic vascular injury that
manifests as kidney damage, serositis, pulmonary hyper-
tension, and multisystem organ failure [6-9]. In the most
severe form of HSCT-TMA, mortality rates approach 90%,
whereas milder cases have an increased risk of chronic
kidney disease [3,8,10]. Targeted therapy is urgentlyedgments on page 525.
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Recently, we showed that patients with HSCT-TMA have
evidence of complement dysregulation, including comple-
ment factor H autoantibodies and renal C4d deposition
[11,12]. HSCT-TMA is a multifactorial disease in which either
the classical or alternative complement pathways may
become activated, resulting in tissue damage from micro-
vessel thrombosis [13]. Currently available therapeutic
options in patients with HSCT-TMA include therapeutic
plasma exchange (TPE), rituximab, and withdrawal of calci-
neurin inhibitors. However, clinical response is often limited,
especially in patients with severe HSCT-TMA. Furthermore,
altering immunosuppressive therapymay increase the risk of
graft-versus-host disease (GVHD), which itself is associated
with high mortality [5,14,15].
Eculizumab, a humanized monoclonal antibody against
the complement component C5 that prevents tissue damage
by blocking formation of the membrane attack complex, is
increasingly prescribed in the treatment of other diseases
presenting with TMA [16-19]. Eculizumab has a low toxicity
proﬁle and has been well tolerated in patients withTransplantation.
Table 1
Patient Demographics and Disease Characteristics
Responders Non-responders
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Gender F F M F M M
Age at HSCT, y 4.9y 5.1y 2.4y 4.3y 7.2y 10.9y
Weight, kg 4.9 5.1 2.4 4.3 7.2 10.9
Diagnosis NBL NBL WAS CID WAS CID
Stem cell source Autologous Autologous Allogeneic Allogeneic Allogeneic Allogeneic
HSCT conditioning
regimen
MA MA MA RIC MA RIC
Day post-HSCT when
TMA was
diagnosed
13 68 390 6 41 57
Cystatin C-eGFR (mL/
min) at TMA
diagnosis
48 20 16 30 15 17
Renal replacement
therapy at TMA
diagnosis
No No Yes No No Yes
Urine protein-to-
creatinine ratio
(normal <.2 mg/
mg, nephrotic >2
mg/mg)
81.6 11.3 4.5 10.6 14.1 6.4
HSCT-TMAerelated
complications
HTN, PH, pericardial
effusion
HTN, pericardial
effusion
HTN, pericardial
tamponade
HTN, PRES, seizures,
pericardial effusion
HTN, pulmonary
bleeding
HTN, pericardial
effusion
Complement proﬁle* [C2, [C6, [CFB YC4 YC4 [C5, [C7, [C4BP [ C8, [C1Inhib, Y
CFH
[ C1Q, [C4, [C8
sC5b-9 (normal, 119
to 17 5 ng/mL)
283 307 139(on TPE) 328 432 375
CFH antibody Absent Absent Absent Absent Absent Absent
CFHR3-CFHR1 (by
MLPA)
Not tested Normal Heterozygous
deletion
Normal Not tested Not tested
CFHR1 protein Present Present Present Present Present Present
Renal biopsy/autopsy Not done TMA, C4d deposits in
arterioles
Not done Not done Not done TMA
Infections None None None None None Adenovirus, BK, and
HSV viremia
Acute GVHD n/a n/a Yes (skin) No Yes (skin, gut) Yes (skin, gut)
Eculizumab start
from HSCT-TMA
diagnosis, days
3 40 122 26 24 97
Number of
eculizumab doses
given
9 13 6 4 7 2
Number of TPE
sessions done
before starting
eculizumab
None 32 79 15 24y 17y
NBL indicates neuroblastoma; WAS, Wiskott-Aldridge syndrome; CID, combined immunodeﬁciency; MA, myeloablative regimen; RIC, reduced intensity
regimen; HTN, systemic hypertension; PH, pulmonary hypertension; PRES, posterior reversible encephalopathy syndrome; HSV, herpes simplex 1 virus; MLPA,
multiplex ligation-dependent probe ampliﬁcation; Del (CFHR3-CFHR1), heterozygous deletion of CFH gene 3 and 1; n/a, not applicable.
* Complement proﬁle includes C1inhib, complement component 1 inhibitor; C1Q, complement component 1q complex; C2-C9, complement components 2-9;
C4BP, C4d binding protein; complement factors (CF) F, B, H, and I.
y Died while on eculizumab therapy.
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lytic uremic syndrome (aHUS). It has been approved for use in
children with aHUS, and a pediatric weight-based dosing
schedule has been established [20]. It is unknown if eculizu-
mab is effective in childrenwithHSCT-TMA and if the existing
dosing regimen adequately blocks complement in these pa-
tients. Therefore, we describe our clinical experience in a
cohort of children treated with eculizumab for severe HSCT-
TMA and propose an algorithm to adjust the dosage and
monitor therapeutic response based on our observations.METHODS
Patient Population
Six patients with severe HSCT-TMA were treated with eculizumab
(Alexion, Cheshire, CT) at Cincinnati Children’s Hospital Medical Center
(CCHMC) between January 2012 and May 2013. The CCHMC InstitutionalReview Board approved retrospective chart review. Patient demo-
graphics, therapy characteristics, and HSCT complications were
abstracted from the medical record. HSCT-TMA was diagnosed using
current diagnostic criteria and included elevated lactate dehydrogenase
above normal for age, haptoglobin below the lower limit of normal,
schistocytes on peripheral blood smear, anemia, thrombocytopenia, a
negative Coombs test, and acute kidney injury, deﬁned as a doubling of
the serum creatinine or a 50% decline in the cystatin Ceestimated
glomerular ﬁltration rate (eGFR) from each subject’s pre-HSCT baseline
[5,21,22]. Proteinuria was identiﬁed using a random spot urine protein-
to-creatinine ratio (normal <.2 mg/mg, nephrotic range >2 mg/mg)
[23,24]. Kidney biopsy results, if available, were reviewed for histology
of TMA.
Each subject’s legal guardian signed informed consent for treatment
with eculizumab. The decision to start eculizumab was at the discretion of
the treating physician but generally included severe TMA presenting with
multiorgan impairment, uncontrolled hypertension, worsening renal func-
tion, and a lack of response to TPE and withdrawal of calcineurin inhibitors
in allogeneic transplant recipients.
Table 2
Response to Eculizumab Therapy in Patients with HSCT-TMA
Responders Non-responders
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Response to eculizumab
Therapeutic eculizumab level (trough) after ﬁrst dose No No Yes Yes No No
Therapeutic eculizumab level (trough) after subsequent doses Yes Yes Yes Yes No* No*
Normalization of LDH, d 16 18 27 15 NR NR
Normalization of haptoglobin, d 25 43 15 15 8 NR
Disappearance of schistocytes, d 30 45 14 7 NR NR
Normalization of hemoglobin without transfusions, d 20 43 23 7 NR NR
Recovery of platelets to 20,000 K/mL, d 18 43 14 7 NR NR
Recovery of platelets to 50,000 K/mL, d 30 45 14 7 NR NR
Doubling of cystatin CeeGFR, d 31 95 141 16 NR NR
Urine protein-to-creatinine ratio <2 mg/mg, d 19 108 63 29 NR NR
Number of anti-HTN medication at the start of eculizumab therapy 7 6 6 9 6 7
Number of anti-HTN medication at the end of eculizumab therapy 0 1 2 2 4 2
Hematologic HSCT-TMA response, d 30 45 27 15 NR NR
Complete resolution of HSCT-TMA, d 31 108 141 29 NR NR
Outcomes
Current status Alive Alive Alive Alive Dead Dead
Time from starting eculizumab therapy to the last encounter, weeks 38 55 40 72 5 <2
Most current cystatin CeeGFR, mL/min 138 48 41 150 n/a n/a
Most current random urine protein-to-creatinine ratio
(normal <.2 mg/mg, nephrotic range >2 mg/mg)
.2 .9 .48 .14 n/a n/a
LDH, lactate dehydrogenase; HTN, hypertension; NR, no response.
* Did not achieve therapeutic eculizumab level even with the dose escalation.
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A hematologic response to eculizumab was deﬁned as normalization of
lactate dehydrogenase and haptoglobin, resolution of the need for RBC and
platelet transfusions, and disappearance of schistocytes. A complete
responsewas deﬁned as normalization of the hematologic parameters noted
above combined with a doubling of the cystatin CeeGFR and improvement
of proteinuria to values below the nephrotic range, as deﬁned by a random
spot urine protein-to-creatinine ratio <2 mg/mg [25].
Complement Assessments
Assessment of the complement proﬁle was performed at the time of
HSCT-TMA diagnosis. Testing included measurement of complement pro-
teins (Table 1), soluble terminal complement complex activity (sC5b-9), and
autoantibodies to complement factor H (CFH) [11,26,27]. ADAMTS13 activity
was measured to rule out thrombotic thrombocytopenic purpura. These
studies were performed at the CCHMC clinical laboratory. Circulating CFH-
related 1 protein (CFHR1) testing was performed on recipients’ plasma to
exclude a CFHR1 homozygous deletion. CFHR1 was detected by immuno-
blotting (Division of Nephrology, The Hospital for Sick Children, Toronto,
Ontario, Canada), as previously described [28,29]. CFH-related genes 3 and 1
(CFHR3-CFHR1) were examined in stored pretransplant (recipient) DNA
samples by multiplex ligation-dependent probe ampliﬁcation testing
(MORL Laboratory, University of Iowa, Iowa City, IA) [30,31].
Eculizumab Treatment and Monitoring
In patients receiving TPE, treatment was stopped before starting eculi-
zumab so as not to remove the drug. The ﬁrst dose of eculizumab was given
according to recommendations for childrenwith aHUS [20]. Eculizumabwas
infused via central venous access over 60 minutes. Because immunocom-
promised HSCT recipients do not respond to meningococcal vaccination, all
patients were maintained on ciproﬂoxacin or penicillin VK prophylaxis until
eculizumab was cleared and the CH50 levels normalized.
Because dosing recommendations to guide eculizumab therapy in HSCT
recipients are not available, eculizumab serum levels were tested at least
twice a week after each dose and always included a trough level drawn
before each dose. Eculizumab drug levels were performed at Cambridge
Biomedical, Inc. (Boston, MA), and we adjusted the dose to maintain a
trough concentration >99 mg/mL, because this drug level has been consid-
ered therapeutic in patients with aHUS [16]. Patients weighing <40 kg
started with 600 mg i.v., and patients weighing 40 kg started with 900 mg
i.v. as a ﬁrst dose. Subsequent dose adjustments were as follows: If a trough
level was reported as therapeutic before the next weekly dose, the same
induction dose was continued weekly. If the patient was due for the next
weekly dose and the eculizumab trough concentration was subtherapeutic,
the dose was increased by 300 mg/dose. If a subtherapeutic result was re-
ported 4 to 5 days after the prior dose, an extra induction dose was given
when the result was obtained. If results were not available for doseadjustment, the same eculizumab induction dose was continued weekly
until the trough eculizumab concentrationwas documented to be above the
therapeutic level. Laboratory markers of TMA were documented daily dur-
ing inpatient stay and at least twice weekly in the outpatient setting.
Weekly induction therapy was continued until patients achieved a he-
matologic TMA response and had documented eculizumab levels >99 mg/
mL, at which point a maintenance schedule was started (see Figure 3B). The
criteria for stopping eculizumab included normalization of hematologic
TMA parameters and improvement in renal function.
Pharmacokinetic and Pharmacodynamic Analyses
Total hemolytic complement activity (CH50) was measured in serum
during eculizumab therapy as a pharmacodynamic marker of eculizumab-
induced complement blockage, at the same time points as eculizumab
drug levels. We correlated eculizumab drug levels with the degree of
complement blockade as measured by CH50. A normal CH50 level was 60 to
144 complement activity enzyme (CAE) units (ARUP Laboratories, Salt Lake
City, UT) [32].
The pharmacokinetic proﬁling of eculizumab was performed at the Di-
vision of Clinical Pharmacology, CCHMC, and was described by a 1-
compartment model because the eculizumab concentrations showed an
exponential decline over time. The elimination rate constant (kel) and
concentration at 0 (C0) were estimated by linear least-squares regression of
the log-transformed concentrations versus time in the log-linear phase of
the disposition proﬁle. Apparent volume of distribution (Vd) was estimated
based on dose/C0 in the ﬁrst treatment. Apparent systemic clearance (CL)
was calculated by the formula CL (L/h) ¼ kel  Vd. Maximum eculizumab
concentrations in the nth dose (Cmax,n) were determined by the following
equation: Cmax,n ¼ Ctrough, n-1 þ dose/Vd. Receiver operating characteristic
curve analysis and Youden’s index were used to ﬁnd the best cut-off value of
CH50 that predicted a therapeutic eculizumab trough level > 99 mg/mL.
RESULTS
Patient Characteristics
Six children with severe HSCT-TMA received eculizumab
therapy; patient characteristics are shown in Table 1. Median
patient age was 5 years (range, 2.4 to 10.9 years). HSCT-TMA
was diagnosed within 100 days (range, 6 to 69 days) of
transplant in 5 patients. One patient was diagnosed 1 year
post-transplant after presenting with acute HSCT-TMA and
renal failure requiring hemodialysis. At diagnosis of HSCT-
TMA, all patients had impaired renal function with a me-
dian serum cystatin CeeGFR of 18.5 mL/min (range, 15 to
48 mL/min) and nephrotic range proteinuria with a median
Figure 1. Pharmacokinetic and pharmacodynamic analyses of eculizumab therapy in 6 patients with HSCT-TMA during the ﬁrst 3 weeks of treatment are displayed.
The left and right y axes show eculizumab concentrations and total complement activity (CH50) levels, respectively. The x axis shows time as days from the start of
eculizumab therapy with the ﬁrst eculizumab dose given on day 1. Dosage (mg) and the timing of administration are indicated with arrows on the top of each ﬁgure.
Asterisk (*) marks eculizumab doses that are either higher than currently recommended for children with aHUS based on dosing weight or given more frequently
[20]. Blue circles represent observed eculizumab concentrations. Actual measured values are noted beside the circles only when eculizumab concentration is below
99 mg/mL. Blue dashed lines represent predicted eculizumab pharmacokinetic proﬁles based on a 1-compartment analysis (see Methods for detail). Red circles
represent the CH50 level. The actual values are listed on the graph only when the CH50 level is above 3 CAE units. Red circles are connected with red solid or dashed
lines when measurement of CH50 levels are continuous (daily) or intermittent, respectively. In patient 6, the ﬁrst 3 measurements days 2, 3, and 4 were used to
estimate pharmacokinetic parameters (kel, CL) because concentrations of eculizumab irregularly showed a bi-exponential decline with very low concentrations at the
last 3 measurements on days 5, 6s and 7. The Vd for this patient was calculated based on the second treatment.
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(range, 4.5 to 81.6 mg/mg). Two patients required renal
replacement therapy. All patients had severe hypertension
requiring 6 to 9 antihypertensive medications at initiation of
eculizumab therapy. ADAMTS13 activity level was normal
(>67%) in all patients, ruling out thrombotic thrombocyto-
penic purpura.
More speciﬁcally, patient 1 was treated with eculizumab
without attempting TPE because she had acute develop-
ment of HSCT-TMA with uncontrolled hypertension and
was not considered a suitable candidate for apheresis line
placement under anesthesia. Patient 2 had progressive
renal function decline and was approaching the need for
renal replacement therapy. Renal biopsy showed >90% of
glomeruli affected by TMA. Diffuse C4d staining was
evident in TMA affected renal arterioles indicating com-
plement deposits, as previously described [12]. Patient 3
had exacerbation of HSCT-TMA symptoms and progressive
hypertension with each attempt to wean TPE. Patient 4
developed seizures and posterior reversible encephalopa-
thy syndrome and was on 9 antihypertensive medications
with blood pressures still above 99% for her age and height
before initiation of eculizumab. Patients 5 and 6 werecritically ill with acute GVHD, viral infections, and multi-
organ failure in addition to HSCT-TMA before initiation of
eculizumab.
Cyclosporine was discontinued in all 4 allogeneic trans-
plant recipients at diagnosis of HSCT-TMA due to kidney
injury or the development of posterior reversible encepha-
lopathy syndrome/seizures and was replaced with steroids
and/or mycophenolate mofetil. Three of these patients had
active acute GVHD at diagnosis of TMA. Patient 3 had acute
stage III skin GVHD (overall grade II GVHD) and was treated
with mycophenolate mofetil and methylprednisolone 1 mg/
kg/day. GVHD improved sufﬁciently by the end of eculizu-
mab therapy to allow weaning of anti-GVHD medications.
Patient 5 had acute ocular GVHD, acute stage III skin GVHD,
and acute stage II gut GVHD (overall grade III GVDH) at TMA
diagnosis and was treated with mycophenolate mofetil,
methylprednisolone 2 mg/kg/day, and inﬂiximab with reso-
lution of all but ocular GVHD by the time he died from
multiorgan failure. Patient 6 had acute stage II gut GVHD
with intermittent intestinal bleeding at HSCT-TMA diagnosis
and was treated with methylprednisolone 2 mg/kg/day and
inﬂiximab. Intestinal bleeding persisted during eculizumab
therapy until patient’s family opted to withdraw clinical
Figure 2. Relationship between eculizumab concentration and total comple-
ment activity (CH50) level. Using the reported therapeutic eculizumab trough
cut-off level of >99 or 99 mg/mL, the receiver operating characteristic curve
and Youden’s Index were used to determine the optimal CH50 cut-off level of
3.5 CAE units. The y axis shows eculizumab concentrations in log-scale. The
x axis shows the CH50 level as a group. Horizontal lines represent medians. A
CH50 level of 0 to 3 CAE units corresponded with an eculizumab concentration
of >99 mg/mL in all except 1 measurement (drawn from patient 6 during an
extremely rapid elimination phase in the ﬁrst week of therapy). Conversely, at
all sampling time points, a CH50 level >3 CAE units corresponded with a
subtherapeutic level < 99 mg/mL (P ¼ .0001, Mann-Whitney U test).
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GVHD coincident with severe intestinal TMA.
Complement Assessments
Terminal complement complex activity (sC5b-9) was
elevated in 5 of 6 patients (Table 1). The patient with a
normal sC5b-9 level was receiving TPE when the blood
sample was obtained. CFH autoantibody was not detected in
any patient. Two patients had decreased C4 levels and 1
decreased CFH levels. All patients had detectable CFHR1
protein, ruling out a homozygous deletion of CFHR3-CFHR1.
One of 3 patients tested with multiplex ligation-dependent
probe ampliﬁcation testing had a heterozygous CFHR3-
CFHR1 deletion. Renal biopsy performed on patient 2 showed
severe TMA with diffuse C4d staining in affected arterioles
[12]. Patient 6 had renal TMA conﬁrmed on autopsy.
Clinical Response to Eculizumab
Patients 1 to 4 had complete clinical responses to eculi-
zumab after achieving therapeutic eculizumab levels
(Table 2). A median of 7 doses (range, 4 to 13 doses) of
eculizumab were required to resolve HSCT-TMA. All surviv-
ing patients weighing < 40 kg received eculizumab 600 mg
i.v. and those weighing  40 kg received 900 mg i.v. at least
weekly for at least 4 weeks before any consideration was
given to advance the dosing schedule. A hematologic TMA
response in these 4 patients was observed a median of
28.5 days (range,15 to 45 days) after initiation of eculizumab.
All 4 responders had a dramatic improvement in hyperten-
sion with a reduction in the number of antihypertensive
medications from 6 to 9 at the start of eculizumab therapy to
0 to 2 medications at eculizumab therapy completion. The
median time for a complete response of all HSCT-TMA pa-
rameters, including doubling in cystatin CeeGFR and
improvement of proteinuria below 2 mg/mg, was 69.5 days
(range, 29 to 141 days) after eculizumab initiation.
All responders were doing well at a median of 47.5 weeks
(range, 38 to 72 weeks) post-diagnosis of HSCT-TMA. Pa-
tients 1 and 4 completely recovered renal function as evi-
denced by normal cystatin CeeGFR >100 mL/min and the
absence of proteinuria and hypertension. Patients 2 and 3,
both of whom had prolonged severe kidney injury due to
HSCT-TMA at the start of eculizumab therapy, remain with
chronic kidney disease and a cystatin CeeGFR <50 mL/min
but are off hemodialysis and normotensive on losartan
therapy.
Patients 5 and 6 died from multisystem organ failure and
active HSCT-TMA while receiving eculizumab. These 2 pa-
tients were older (and weigh more) than the 4 patients who
responded to treatment. Both patients were critically ill with
severe multiorgan injury at the time of starting eculizumab
therapy, and neither achieved sustained therapeutic eculi-
zumab trough levels or complement blockade, as measured
by CH50 (Figure 1). All 6 patients tolerated eculizumab
therapy without any side effects or reactions, and there were
no meningococcal infections or other bacterial infections.
Eculizumab Pharmacokinetics
Eculizumab dosing and drug levels during the ﬁrst
3 weeks of therapy are shown in Figure 1. Four of 6 patients
had subtherapeutic eculizumab through levels after the ﬁrst
dose. Notably, the ﬁrst eculizumab dose for patient 3 was
higher (600 mg) than recommended (300 mg) for his weight
of 9 kg, producing a therapeutic level after the ﬁrst dose. This
child was the only patient who achieved and maintained atherapeutic eculizumab level after the ﬁrst dose, which may
have been associated with a faster clinical response. Thera-
peutic trough levels of eculizumab >99 mg/mL were even-
tually achieved in all 4 responders (patients 1 to 4) using
either extra doses or doses that were higher than currently
recommended (Figure 1). Eculizumab trough levels
remained subtherapeutic in the 2 nonresponding cases (pa-
tients 5 and 6). Patient 5 did not achieve a therapeutic trough
level during 5 weeks of therapy, despite signiﬁcant dose
escalation to 900 mg twice weekly, starting on day 24 of
therapy (data not shown in Figure 1). Patient 6 received 2
weekly induction doses of 900 mg, as recommended for his
weight, before he died. In both nonresponders, the eculizu-
mab level dropped below therapeutic 3 days after the ﬁrst
dose, but results were pending so dosing could not be
adjusted in a timely manner. Elimination rate constants and
systemic clearance of eculizumab showed signiﬁcant vari-
ability among patients, with the most rapid clearance in
patients 5 and 6 who were most ill at the time of treatment
and perhaps more highly catabolic than the responding pa-
tients (data not shown).Relationship between Eculizumab Levels and CH50
Eculizumab and CH50 levels that were measured at the
same time points strongly correlated with each other
(Figures 1 and 2). Speciﬁcally, a CH50 level of 0 to 3 CAE units
corresponded with an eculizumab concentration >99 mg/mL,
except for 1 measurement from patient 6, drawn during an
extremely rapid elimination phase in the ﬁrst week.
Conversely, at all sampling time points with a CH50 count 
4 CAE units, the patients’ eculizumab concentrations were
below therapeutic at <99 mg/mL (P ¼ .0001).
Complete blockade of complement activity (CH50 < 3
CAE units) was achieved in all 4 responders (patients 1 to 4)
after the second dose of therapy (Figure 1). Complement
Figure 3. Eculizumab dosing optimization in HSCT patients with TMA. (A) Suggested eculizumab dose adjustments based on CH50 level and clinical TMA response.
(B) Eculizumab induction and maintenance doses based on patient’s weight (modiﬁed from dosing schedule for children with aHUS [20]). CH50 should be monitored
daily after the ﬁrst eculizumab induction dose is given with the goal to maintain CH50 level of 0 to 3 CAE units that corresponds to a therapeutic eculizumab dose
>99 mg/mL. If CH50 remains 0 to 3 CAE units after start of therapy, the induction dose should be given weekly until full resolution of hematologic parameters of TMA
before advancing to maintenance schedule. If CH50 is  4 CAE units earlier than 7 days after starting therapy, an additional induction dose should be given. If CH50
raises again to 4 CAE units, the next dose should be increased by 300 mg to achieve a steady therapeutic level as soon as possible. The dose of eculizumab that
maintains a CH50 level 3 CAE units is the required weekly induction dose for the particular patient. During maintenance therapy, CH50 should be monitored at least
twice a week to ensure a therapeutic drug level.
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(patients 5 and 6).
DISCUSSION
We report the ﬁrst use of the terminal complement in-
hibitor eculizumab in children with severe HSCT-TMA. We
observed that 4 of 6 children had complete resolution of se-
vere HSCT-TMA after achieving steady therapeutic eculizu-
mab levels. The 2 remaining patients, who were critically ill
when therapy was initiated, died without achieving thera-
peutic drug levels or complement blockade, despite dose
escalation. The 2 nonresponders were also older than the 4
responders, an observation that deserves future study. All
children with HSCT-TMA required higher eculizumab dosing
and/or more frequent drug administrations to reach and
maintain therapeutic eculizumab trough levels > 99 mg/mL
compared with the dosing regimen currently recommended
for children with aHUS [20].
Measurement of eculizumab levels in our patient cohort
was of signiﬁcant value in understanding the drug’s phar-
macokinetics in children after HSCT. Pharmacokinetic
analysis showed that 3 of 6 patients had eculizumab sub-
therapeutic drug concentrations < 99 mg/mL as soon as 4 to
5 days after the ﬁrst eculizumab infusion and required an
additional eculizumab dose to achieve a therapeutic drug
trough level. Also, the rate of eculizumab elimination was
not constant after every treatment but decreased over time
and stabilized as represented by a declining slope of the
log-transformed eculizumab concentration, which becameshallower after multiple treatments indicating that doses
could be administered with longer intervals. After steady
therapeutic eculizumab serum concentrations were ach-
ieved, younger patients in our cohort were able tomaintain a
much higher drug level than targeted (>99 mL/mL) without
any adverse events and with notable improvement in TMA-
related symptoms. The current literature reports no signiﬁ-
cant adverse events attributed to high eculizumab levels,
outside the known risk of infection. Unfortunately, eculizu-
mab drug levels are only available from 1 laboratory in the
United States (Cambridge Biomedical, Inc.), and results are
often not available for 1 to 2 weeks. This long turnaround
time may delay needed dose adjustment and prevent the
achievement of complement blockade in HSCT patients
treated with eculizumab. We speculate that earlier adjust-
ments to dosing may have allowed treatment to be more
effective in controlling TMA and preserving organ function in
some of our patients.
In contrast, CH50 represents a pharmacodynamic mea-
sure of complement activity and is more readily available in
most institutions, with a result turnaround time of 1 to
2 days. Therefore, CH50 testing during eculizumab therapy in
HSCT patients may offer a more rapid assessment of com-
plement blockade, allowing for practical dose adjustments in
a more timely fashion. Our proposed dosing schedule
modiﬁcation based on CH50 level is displayed in Figure 3. In
our study, only a CH50 level< 4 CAE units strongly correlated
with a therapeutic eculizumab level > 99 mg/mL and clinical
TMA response, indicating successful complement blockade
Figure 4. Complement activation in pathogenesis of HSCT-TMA. Factors
involved in classic and alternative pathway activation in patients with HSCT-
TMA. The classic pathway can be activated by direct tissue injury from high-
dose chemotherapy, viruses, and GVHD. C4d deposits, as the evidence of
classic complement pathway activation, can be detected in renal arterioles of
HSCT patients affected with TMA [12]. Alternative pathway dysregulation
might present as a formation of the pathogenic autoantibody against com-
plement factor H (CFH ab) due to either defects in CFHR3-CFHR1 genes asso-
ciated with defective or absent CFHR1 protein or immune dysregulation after
HSCT without genetic predisposition [11]. Dysregulation in either the classic or
alternative pathway of complement results in terminal complement activation
detected as elevated sC5b-9 (MAC) that can be blocked by eculizumab, which
inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which pre-
vents the generation of the terminal complement complex C5b-9 and tissue
injury.
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CH50 levels of 0 to 3 CAE units (or CH50 activity below 5%)
should be maintained during eculizumab treatment to
ensure the best therapeutic response.
Our study also provides important data regarding the
time to clinical response with eculizumab in children with
HSCT-TMA. Even though resolution of severe TMA took
several weeks in responding patients, similar to aHUS, the
fastest and most complete response was achieved in patients
who started eculizumab therapy promptly after the diag-
nosis of HSCT-TMA and sustained steady therapeutic eculi-
zumab levels and complement blockade [16]. However, we
were able to achieve a hematologic response and control of
hypertension even in patients with a prolonged course of
HSCT-TMA that was previously refractory to TPE. In cases
with prolonged HSCT-TMA before eculizumab therapy, renal
recovery was incomplete and the time to recovery was
longer, but all responders exhibited continuous, time-
dependent improvement in renal function, suggesting that
early use of eculizumab may maximize beneﬁt in cases of
severe HSCT-TMA.
Based on our clinical and pharmacologic observations, we
suggest at least 4 to 6 weeks of induction therapy with a
documented therapeutic eculizumab trough level or
adequate complement blockade (low CH50) before calling a
patient a nonresponder. If a patient is determined to be a
rapid eliminator after the ﬁrst induction dose (ie, 3 to 4 days
after therapy initiation), an additional eculizumab induction
dose should be considered to achieve a therapeutic trough
level as quickly as possible. The CH50 level should be
measured daily during induction therapy. In patients who fail
to achieve full complement blockade, we suggest increasing
the eculizumab dose by 300 mg above the currently rec-
ommended induction dose (Figure 3). As demonstrated byour 2 nonresponding subjects, those with additional com-
plications such as GVHD and viral infections may be highly
catabolic with concomitant activation of terminal comple-
ment. It may be challenging to achieve therapeutic levels of
eculizumab needed to block complement and control TMA.
Administration of eculizumab in critically ill HSCT patients
without proper monitoring may provide only intermittent or
no complement blockade, leading to the conclusion that
eculizumab does notwork in controlling TMAwhile in reality
inadequate dose is being administered.
Five patients in our cohort had elevated sC5b-9, indi-
cating an activated terminal complement pathway that could
be caused by either alternative or classic complement dys-
regulation as previously described by our group of patients
with HSCT-TMA [11,12]. Differences in the pathogenesis of
HSCT-TMA occurring after allogeneic and autologous HSCT
remain to be examined. We observed that autologous HSCT
recipients present with evidence of classic pathway activa-
tion with a low C4 level, C4d deposition in the kidney, and
severe multiorgan injury that may result from direct damage
to the vascular endothelium from conditioning chemo-
therapy. Conversely, after allogeneic HSCT, we observed that
some patients have evidence of alternative pathway activa-
tion with the presence of CFH antibodies. Nevertheless,
complement activated by either the alternative or classic
pathway can be blocked by the terminal complement blocker
eculizumab, making this medication an appropriate therapy
regardless of the complement pathway involved in patho-
genesis of HSCT-TMA (Figure 4) [20,33].
Although patients with paroxysmal nocturnal hemoglo-
binuria and aHUS are often committed to life-long therapy
with eculizumab, some HSCT patients may develop TMA due
to infections or temporary immune dysregulation without a
genetic predisposition, suggesting that eculizumab therapy
can be discontinued in these patients after TMA is controlled.
We were able to stop eculizumab therapy in all 4 responders
after achieving a hematologic and renal response. The
shortest successful course was 4 weeks, and the longest
therapy was 15 weeks. There were no recurrences of HSCT-
TMA in the 4 responders after stopping therapy.
To consider stopping eculizumab therapy, we ﬁrst suggest
achieving full resolution of hematologic TMAmarkers during
induction therapy with the steady therapeutic eculizumab
level and full complement blockade documented by low a
CH50 level. After achieving hematologic TMA control and
improvement in renal function, eculizumab can be advanced
to a maintenance schedule. Hypertension must be well
controlled in all patients with a target systolic blood pressure
below the 95th percentile for age and height [34]. Only after
ensuring TMA is well controlled on a maintenance dosing
regimen, eculizumab may be stopped while TMA markers
are closely monitored (Figure 3).
In conclusion, eculizumab is a promising therapeutic
option for pediatric patients with severe HSCT-TMA. In our
practice, we consider eculizumab as a ﬁrst-line therapy in
patients who present with acute-onset HSCT-TMA with sig-
niﬁcant microangiopathic hemolysis, severe hypertension, or
evidence of multiorgan involvement or in patients with
subacute TMA whose symptoms progress within 2 weeks of
observation and supportive care. We believe that early
therapy initiation with eculizumab may prevent irreversible
organ damage, and toxicity is low. Eculizumab dosing in
children with HSCT-TMA should be guided by pharmacoki-
netic or pharmacodynamic testing, and more aggressive
dosing schedules need to be explored in the most ill and
S. Jodele et al. / Biol Blood Marrow Transplant 20 (2014) 518e525 525catabolic patients. CH50 monitoring may aid in timely dose
adjustments, especially in highly catabolic patients, likely
requiring drug administration more than once a week.
Controlled studies of this approach in both children and
adults after HSCT are warranted to further examine clinical
response and the beneﬁt of therapeutic monitoring.
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